SCHEMBL5887437

SCHEMBL5887437

Cc1nc(N2CCN(Cc3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NC2CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
KMT2A Q03164 2/20 0.50
TSHR P16473 2/20 0.50
CASP1 P29466 1/20 0.50
GAA P10253 1/20 0.50
MEN1 O00255 1/20 0.48
TMEM97 Q5BJF2 2/20 0.47
SIGMAR1 Q99720 2/20 0.47
SLC6A12 P48065 2/20 0.47
MCHR1 Q99705 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
TP53 P04637 2/20 0.47
THRB P10828 1/20 0.46
KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887542 0.90 MAPK8 (0.45) LMNASMN1; SMN2TSHR
SCHEMBL5887124 0.89 LMNA (0.45) LMNASMN1; SMN2KMT2ATSHRCASP1
SCHEMBL5887427 0.89 SMN1; SMN2 (0.46) LMNASMN1; SMN2KMT2ATSHRCASP1
SCHEMBL5887366 0.88 ALDH1A1 (0.47) LMNASMN1; SMN2KMT2ATSHRMEN1
SCHEMBL5887300 0.87 SMN1; SMN2 (0.43) LMNASMN1; SMN2KMT2ATSHRCASP1
SCHEMBL5887495 0.87 MEN1 (0.46) LMNASMN1; SMN2KMT2AMEN1MCHR1
SCHEMBL5886852 0.86 LMNA (0.46) LMNASMN1; SMN2KMT2ATSHRCASP1
SCHEMBL5886718 0.86 CCNE1 (0.45) KMT2AMEN1
SCHEMBL5887033 0.86 MAPK8 (0.40) LMNASMN1; SMN2TSHR
SCHEMBL5887242 0.86 BRD4 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP LMNA 711/4885SMN1; SMN2 2219/4885KMT2A 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.